TY - CHAP M1 - Book, Section TI - Multimodality Therapy for Esophageal Cancer: Eastern Experience A1 - Sohda, Makoto A1 - Miyazaki, Tatsuya A1 - Yokobori, Takehiko A1 - Sakai, Makoto A1 - Kuwano, Hiroyuki A2 - Morita, Shane Y. A2 - Balch, Charles M. A2 - Klimberg, V. Suzanne A2 - Pawlik, Timothy M. A2 - Posner, Mitchell C. A2 - Tanabe, Kenneth K. Y1 - 2018 N1 - T2 - Textbook of Complex General Surgical Oncology AB - The majority of esophageal carcinomas are represented by two histologies: squamous cell carcinoma and adenocarcinoma. Esophageal squamous cell carcinoma (ESCC) is the predominant histological type in Asia. Although treatment strategies differ slightly between Western and Asian countries, surgery traditionally remains the standard therapy for esophageal cancer. However, survival after surgery alone remains poor because of the high rates of local and systemic failure. Thus, multimodality therapies using various combinations of all modalities including surgery, radiotherapy, chemotherapy, and chemoradiotherapy (CRT) have been investigated. In this chapter, we described recent issues regarding multimodality therapy for esophageal cancer in Eastern countries. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/28 UR - accesssurgery.mhmedical.com/content.aspx?aid=1145761234 ER -